Status:
COMPLETED
Seroquel on Glucose Metabolism
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism
Eligibility Criteria
Inclusion
- In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent.
Exclusion
- Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT.
- Previous use of atypicals (3 months) or other medications that might influence glucose metabolism
- Contraindications or non-responsiveness for any of the treatments or other safety issues
- Expected non-compliance to treatment and/or study procedures
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
572 Patients enrolled
Trial Details
Trial ID
NCT00214578
Start Date
April 1 2004
End Date
October 1 2005
Last Update
January 4 2013
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Burgas, Bulgaria
2
Research Site
Rousse, Bulgaria
3
Research Site
Sofia, Bulgaria
4
Research Site
Sofia- Novi Iskar, Bulgaria